Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03673020 · ClinicalTrials.gov registry record · Phase 1
Phase 1a Study to Evaluate Immunogenicity of ASV®
A Phase 1 study, sponsored by Agenus.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03673020 is a Phase 1 study that has completed, run by Agenus. The registered enrollment target is 3 participants.
The verdict
NCT03673020, a Phase 1 study, has completed, sponsored by Agenus.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection.
Interventions
- BIOLOGICAL ASV® AGEN2017 + QS-21 Stimulon® adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2021-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03673020
The ClinicalTrials.gov registry entry for NCT03673020 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASV® AGEN2017 + QS-21 Stimulon® adjuvant is the first listed.
NCT03673020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03673020 about?
NCT03673020 is a clinical study titled "Phase 1a Study to Evaluate Immunogenicity of ASV®". This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection.
What is the current status of trial NCT03673020?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-05-16. Estimated completion is 2021-02-03.
What interventions are being tested in trial NCT03673020?
The interventions under investigation include: ASV® AGEN2017 + QS-21 Stimulon® adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT03673020?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.